ZFIN ID: ZDB-FISH-150901-2160
Fish name: jh1Tg
Genotype: jh1Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by jh1Tg
No data available
GENE EXPRESSION
Gene expression in jh1Tg
RNA expression
Expressed Gene Structure Conditions Figures
anxa4 standard conditions Fig. 4 with image from Zhang et al., 2014
cabp1b standard conditions Fig. 2 with image from Di Donato et al., 2013
gcga control Fig. S2 with image from Won et al., 2015
ins standard conditions Fig. 3 from Dong et al., 2019
Fig. 4 with image from Dash et al., 2016
Fig. 7 with image,  Fig. 8 with image from Mastracci et al., 2015
Fig. S2 with image,  Fig. S5 with image from Won et al., 2015
Fig. 1 with image from Poulain et al., 2011
chemical treatment by environment: 2-(7-aminoheptyl)guanidine Fig. 8 with image from Mastracci et al., 2015
klf8 standard conditions Fig. S6 with image from Tsai et al., 2015
nkx6.1 standard conditions Fig. 2 with image from Zhang et al., 2017
Fig. 2,  Fig. S2 from Dong et al., 2008
numb control Fig. 7 with image,  Fig. S5 with image from Won et al., 2015
pdx1 standard conditions Fig. 2 with image from Zhang et al., 2017
Fig. 5 with image from Dash et al., 2016
Fig. 2 with image from Mastracci et al., 2015
chemical treatment by environment: eflornithine Fig. 2 with image from Mastracci et al., 2015
prox1a standard conditions Fig. 2 with image from Shin et al., 2012
prss1 control Fig. 1 with image from Mastracci et al., 2015
chemical treatment by environment: eflornithine Fig. 1 with image from Mastracci et al., 2015
ptf1a control Fig. 4 with image from Jusuf et al., 2009
rbpms2b control Fig. 5 with image from Jusuf et al., 2009
sox2 control Fig. 5 with image from Jusuf et al., 2009
tcf7l1a standard conditions Fig. 2 with image from Facchinello et al., 2017
tcf7l1b standard conditions Fig. 2 with image from Facchinello et al., 2017
tcf7l2 standard conditions Fig. 2 with image from Facchinello et al., 2017
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab-5E11 control Fig. 5 with image from Jusuf et al., 2009
Ab2-isl standard conditions Fig. 2 with image,  Fig. 3 with image from Zhang et al., 2017
Fig. 4 with image from Xu et al., 2016
Fig. 3,  Fig. 4,  Fig. S3 from Dong et al., 2008
Ab2-prkcb control Fig. 5 with image from Jusuf et al., 2009
Ab1-smad standard conditions Fig. 4 from Dong et al., 2019
Ab-2F11 standard conditions Fig. 4 with image from Zhang et al., 2014
Fig. 3 with image,  Fig. 4 with image from Matsuda et al., 2013
Fig. 2 with image from Shin et al., 2012
Ab4-krt18 standard conditions Fig. 3 with image from Bielczyk-MaczyÅ„ska et al., 2015
Ab1-GABA control Fig. 5 with image from Jusuf et al., 2009
Ab1-tuba standard conditions Fig. 2 with image from Uribe et al., 2016
Ab1-pvalb control Fig. 5 with image from Jusuf et al., 2009
Ab1-elavl standard conditions Fig. 1 with image from Uribe et al., 2016
Ab4-tjp1 standard conditions Fig. 4 with image from Zhang et al., 2017
Ab2-cpa1 standard conditions Fig. 3 with image from Bielczyk-MaczyÅ„ska et al., 2015
Ab8-prox1 control Fig. 5 with image from Jusuf et al., 2009
Ab-SV2 standard conditions Fig. 2 with image from Lancman et al., 2013
Ab2-ins standard conditions Fig. 2 with image from Lancman et al., 2013
Fig. 3 from Dong et al., 2008
Ab1-pan-Cadherin standard conditions Fig. 2 with image,  Fig. 3 with image from Zhang et al., 2017
Fig. 2,  Fig. 3,  Fig. 4,  Fig. S3 from Dong et al., 2008
Ab3-calb2 control Fig. 5 with image from Jusuf et al., 2009
Ab1-glul control Fig. 5 with image from Jusuf et al., 2009
Ab1-ins ins control Fig. 4 with image from Dash et al., 2016
Ab2-nkx6 nkx6.1 standard conditions Fig. 2 with image from Zhang et al., 2017
Ab3-prox1 prox1a standard conditions Fig. 2 with image from Shin et al., 2012
Fig. 1 with image,  Fig. 3 with image from Poulain et al., 2011
Fig. 2,  Fig. S2 from Dong et al., 2008
Ab1-rbpms2 rbpms2b control Fig. 5 with image from Jusuf et al., 2009
Ab1-sox2 sox2 control Fig. 5 with image from Jusuf et al., 2009
PHENOTYPE
Phenotype in jh1Tg
Phenotype Conditions Figures
endocrine pancreas ins expression decreased amount, abnormal chemical treatment by environment: 2-(7-aminoheptyl)guanidine Fig. 8 with image from Mastracci et al., 2015
endocrine pancreas development disrupted, abnormal chemical treatment by environment: 2-(7-aminoheptyl)guanidine Fig. 8 with image from Mastracci et al., 2015
exocrine pancreas EGFP expression decreased distribution, abnormal chemical treatment by environment: eflornithine Fig. 3 with image from Mastracci et al., 2015
exocrine pancreas EGFP expression decreased distribution, abnormal control Fig. 4 with image from Xu et al., 2016
exocrine pancreas decreased length, abnormal chemical treatment by environment: eflornithine Fig. 1 with image,  Fig. 3 with image from Mastracci et al., 2015
exocrine pancreas decreased length, abnormal chemical treatment by environment: 2-(7-aminoheptyl)guanidine Fig. 8 with image from Mastracci et al., 2015
exocrine pancreas exocrine cell decreased amount, abnormal control Fig. 4 with image from Xu et al., 2016
exocrine pancreas pancreas induction decreased occurrence, abnormal control Fig. 4 with image from Xu et al., 2016
exocrine pancreas development disrupted, abnormal chemical treatment by environment: eflornithine Fig. 1 with image,  Fig. 3 with image from Mastracci et al., 2015
exocrine pancreas development disrupted, abnormal chemical treatment by environment: 2-(7-aminoheptyl)guanidine Fig. 8 with image from Mastracci et al., 2015
extrahepatic duct present, normal standard conditions Fig. 2 with image from Shin et al., 2012
extrapancreatic duct morphology, normal standard conditions Fig. 2 with image from Shin et al., 2012
hindbrain EGFP expression decreased amount, abnormal chemical treatment by environment: eflornithine Fig. 1 with image from Mastracci et al., 2015
islet growth decreased process quality, abnormal chemical treatment by environment: perfluorooctane-1-sulfonic acid Fig. 4 from Sant et al., 2017
liver present, normal standard conditions Fig. 2 with image from Shin et al., 2012
liver development increased occurrence, abnormal control Fig. 4 with image from Xu et al., 2016
pancreas EGFP expression decreased amount, abnormal chemical treatment by environment: eflornithine Fig. 1 with image from Mastracci et al., 2015
pancreas EGFP expression decreased amount, abnormal chemical treatment by environment: 2-(7-aminoheptyl)guanidine Fig. 8 with image from Mastracci et al., 2015
pancreas prss1 expression decreased amount, abnormal chemical treatment by environment: eflornithine Fig. 1 with image from Mastracci et al., 2015
pancreas increased size, abnormal chemical treatment: L-leucine Fig. 4 from He et al., 2017
pancreas size, normal chemical treatment by environment: eflornithine Fig. 1 with image from Mastracci et al., 2015
pancreatic bud pdx1 expression decreased amount, abnormal chemical treatment by environment: eflornithine Fig. 2 with image from Mastracci et al., 2015
pancreatic bud numb expression increased distribution, abnormal control Fig. 7 with image from Won et al., 2015
primary islet has fewer parts of type pancreatic B cell, abnormal chemical treatment by environment: 2-(7-aminoheptyl)guanidine Fig. 8 with image from Mastracci et al., 2015

CITATIONS  (61)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.